FDA Committee Recommends Novo’s Type 2 Diabetes Candidate

An FDA advisory committee unanimously recommended approval of Novo Nordisk’s combination candidate for Type 2 diabetes last week.

The Endocrinologic and Metabolic Drugs Advisory Committee backed the drug as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

“The combination met all the criteria for efficacy,” said Susan Yanovski, co-director of the National Institute of Health’s Office of Obesity Research and a voting member. “I think it had fewer side effects than the individual components and also had the advantage of the once-daily dose.”